Details for Patent: 8,846,695
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,846,695 protect, and when does it expire?
Patent 8,846,695 protects JENTADUETO and TRADJENTA and is included in two NDAs.
This patent has sixteen patent family members in fifteen countries.
Summary for Patent: 8,846,695
Title: | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Abstract: | The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for improving glycemic control in type 2 diabetes patients with inadequate glycemic control despite metformin therapy. |
Inventor(s): | Dugi; Klaus (Dresden, DE) |
Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
Application Number: | 13/143,370 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,846,695 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,846,695
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-003 | Jan 30, 2012 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN | See Plans and Pricing | ||
Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-001 | Jan 30, 2012 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN | See Plans and Pricing | |||
Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-002 | Jan 30, 2012 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN | See Plans and Pricing | |||
Boehringer Ingelheim | TRADJENTA | linagliptin | TABLET;ORAL | 201280-001 | May 2, 2011 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,846,695
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
09150159 | Jan 7, 2009 |
PCT Information | |||
PCT Filed | January 07, 2010 | PCT Application Number: | PCT/EP2010/050103 |
PCT Publication Date: | July 15, 2010 | PCT Publication Number: | WO2010/079197 |
International Family Members for US Patent 8,846,695
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 074990 | See Plans and Pricing | |||
Australia | 2010204331 | See Plans and Pricing | |||
Brazil | PI1006144 | See Plans and Pricing | |||
Canada | 2745039 | See Plans and Pricing | |||
Chile | 2011001635 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |